Effect of Efpeglenatide on Cardiovascular Outcomes

Inclusion criteria:

• T2DM with glycosylated hemoglobin (HbA1c) greater than (>) 7 percentage.
• Age 18 years or older who met at least one of the cardiovascular disease criteria orage 50 years (male), 55 years (female) or older with glomerular filtration rategreater than or equal to 25 and less than 60 milliliters per minute and at least hadone cardiovascular risk factor.
• Female participants agreed to follow contraceptive guidance.
• Signed written informed consent.

Exclusion criteria:

• Clinically relevant history of gastrointestinal disease associated with prolongednausea and vomiting.
• History of chronic pancreatitis or acute idiopathic pancreatitis or diagnosis of anytype of acute pancreatitis within 3 months prior to screening.
• Personal or family history of medullary thyroid cancer.
• Hypertension (with a systolic blood pressure >180 millimeters of Mercury [mmHg] and/ordiastolic blood pressure >100 mmHg).
• Hospitalization for hypertensive emergency within 3 months prior to randomization.
• Planned coronary procedure or surgery after randomization.
• No documented ophthalmologic exam with fundoscopy within 6 months prior torandomization.
• Retinopathy or maculopathy with treatment, either recent (3 months prior torandomization) or planned during the study.
• Treated with any glucagon-like peptide-1 receptor agonist product alone (eg,exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide) or incombination within 3 months prior to screening.
• Use of any Dipeptidyl peptidase 4 inhibitor within 3 months prior to screening.
• Antihyperglycemic treatment had not been stable within 3 months prior to screening. The above information was not intended to contain all considerations relevant to aparticipant's potential participation in a clinical trial.